Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

Transtympanic caroverine by Phafag

Also known as: Caroverin, Caroverine, Tinnitin, NCT01174979, EudraCT 2009-018046-38

Phafag AG

Primary source

Company

Phafag AG

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 3

Status

Paused

Target Gene

—

Route / Mode

Transtympanic ear-drop administration

Confidence

80%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

Austria

Population

adult, older-adult, tinnitus, inner-ear-disease

Trial IDs

Mechanism

Transtympanic caroverine solution evaluated for tinnitus associated with inner-ear disease; caroverine is a small-molecule quinoxalinone reported in public compound sources as caroverine/caroverin.

Indications

Tinnitus Hearing Loss Sudden Hearing Loss Age-Related Hearing Loss

Notes

Verified as a real Phafag-sponsored Phase 3 ClinicalTrials.gov record for transtympanic caroverine in tinnitus/inner-ear disease. The registry reports overall status Suspended, explains the study was suspended because of low patient enrollment, has no posted results, and was last updated in August 2015. HearScape maps this to Paused rather than Active; current onward development or commercialization for this indication was not verified in this pass.

Evidence & Sources

2 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, indications...

IDs: NCT01174979, 2009-018046-38, Phafag AG, Caroverin, Caroverine

Open

compound-database

Supports: aliases, modality, mechanism, notes

IDs: PubChem CID 65709, Caroverine, MSPRUJDUTKRMLM-UHFFFAOYSA-N

Open

Key Events

2010-08-04